https://www.ft.com/content/721b66c6-fd73-432f-aef9-fe59befba2cf
IMUNON Reports Compliance With Nasdaq Listing Requirements
IMUNON, Inc. (NASDAQ:IMNN) ("IMUNON" or the "Company"), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April